UroMems announced that the entire treatment cohort in the first-of-its-kind study in female patients successfully reached its primary endpoints.
A debilitating condition affecting 1 in 4 women is desperately crying out for a solution, and the next generation of treatments to repair the damage of pelvic organ prolapse (POP) has just come a big step closer.
In a study, which has been published in Nature Medicine, a team of researchers from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, shows a new, promising approach
PALO ALTO, Calif., Jan. 21, 2025 /PRNewswire/ — Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma, and medical device partners, today announced that its Glooko XT solution has been approved for reimbursement by the Haute Autorité de Santé (HAS) and the Commission Nationale d’Évaluation des Dispositifs Médicaux et des Technologies de Santé (CNEDiMTS) in France.
IRVINE, Calif., Dec. 2, 2024 /PRNewswire/ — Mentor Worldwide LLC, the number one global brand in breast aesthetics, and part of Johnson & Johnson MedTech, today announced the U.S. Food and Drug Administration (FDA) approved MENTOR™ MemoryGel™ Enhance Breast Implants for primary and revision reconstruction breast surgery in post-mastectomy women.
CHICAGO, Dec. 2, 2024 /PRNewswire/ — ScreenPoint Medical is showcasing a new FDA clearance for innovative new capabilities of its industry leading Breast AI Transpara here at the 110th Annual Radiological Society of North America (RSNA) meeting, December 1-4, 2024 (South Hall #5316)
GE HealthCare (Nasdaq:GEHC) today announced its new Pristina Via mammography system designed to enhance the screening experience.
iCad (Nasdaq:ICAD) announced today that the FDA cleared its ProFound Detection version 4.0 for digital breast tomosynthesis (DBT).
The drug-device combination developed by MIT spinout Lumicell is poised to reduce repeat surgeries and ensure more complete tumor removal.
SimBioSys announced that it received its second FDA 510(k) clearance for TumorSight Viz to expand its use by breast surgeons in the U.S.